Xtx Topco LTD Editas Medicine, Inc. Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 52,558 shares of EDIT stock, worth $70,953. This represents 0.01% of its overall portfolio holdings.

Number of Shares

52,558

Holding current value

$70,953

% of portfolio

0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $178,171 - $313,245	52,558 New	52,558 $179,000
Q1 2024 May 13, 2024	SELL	$7.03 - $11.07 $51,361 - $80,877	-7,306 Reduced 25.19%	21,698 $160,000
Q4 2023 Feb 13, 2024	SELL	$6.25 - $11.11 $61,112 - $108,633	-9,778 Reduced 25.21%	29,004 $293,000
Q3 2023 Nov 13, 2023	SELL	$6.92 - $9.31 $135,161 - $181,842	-19,532 Reduced 33.49%	38,782 $302,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $370,877 - $668,861	58,314 New	58,314 $479,000
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $183,622 - $291,544	22,070 Added 185.34%	33,978 $301,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $144,801 - $231,253	11,908 New	11,908 $146,000
Q2 2021 Aug 12, 2021	SELL	$31.29 - $56.64 $442,002 - $800,096	-14,126 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $560,943 - $1.28 Million	14,126 New	14,126 $593,000

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

Black Rock Inc. New York, NY

7.78M
Shares

$10.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$9.02 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.9M
Shares

$6.62 Million
0.62% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.35M
Shares

$4.52 Million
0.01% of portfolio
State Street Corp Boston, MA

2.46M
Shares

$3.32 Million
0.0% of portfolio

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $92.8M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account